Developer docs
API playgroundTry for free, no card

Search company profiles

Delve Health

Full company profile

uuid0000t82

Namestring
Delve Health
Legal namestring
Delve Health, Inc.
Websiteurl
delvehealth.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Delve Health is a private clinical trial technology company founded in 2020 and headquartered in Minneapolis, Delaware-incorporated. The company operates a unified compliance and retention platform combining eCOA/ePRO, wearable-driven digital endpoints, human concierge patient support, multimedia eConsent, real-time analytics, and device logistics into a single operating model. The platform harmonizes signals from 25+ wearable devices through 70+ validated algorithms spanning ECG, glucose/CGM, activity, sleep, respiratory, and cardiovascular modalities, with alignment to FDA Digital Health Technology guidance, the Digital Medicine Society V3 framework, and ICH E6(R3). Concierge-as-a-Service™ provides protocol-trained human patient support in 120+ languages, delivering secondary screening, device troubleshooting, medication reminders, and site escalation workflows with documented outcomes including 92-98% diary completion, 2-3x retention uplift, and 87% deviation prevention. Compliance certifications span HIPAA, GDPR, FDA 21 CFR Part 11, GCP, ISO 9001, and ISO 27001.

Revenue derives from subscription-based enterprise platform licensing sold via direct sales to pharmaceutical sponsors, biotech, medtech, and research site customers across seven therapeutic areas (dermatology, oncology, rare disease, diabetes/obesity, CNS, cardiology, respiratory). Pricing is quote-based and not publicly disclosed; contracts are multi-year and scoped per study. Named customers include Pfizer, Regeneron, and Otsuka (pharma); Inari (biotech); RTI, Atlas, MCRA, and PDC-CRO (CROs); CVS and Rainier Research (sites). The company operates globally across 40+ countries with 3,500+ devices provisioned and supports CTMS integrations with CRIO and Clinical Conductor, plus open API delivery to EDC systems via REST/webhook with CDISC packages. Total disclosed funding is approximately $609K across four rounds from 2015-2024, including a DayOne accelerator participation in August 2024 and prior gBETA Medtech involvement. Leadership includes co-founder and CEO Wessam Sonbol and CTO T Swidan.

Short descriptiontext

Delve Health provides a unified clinical trial compliance and retention platform combining eCOA/ePRO, wearable digital endpoints, human concierge support, and real-time analytics. The company serves pharmaceutical, biotech, medtech, and research site clients across 40+ countries and seven therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGolden Valley, United States
HQ citystring
Golden Valley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical trial technology, eCOA ePRO platform, digital biomarkers, decentralized clinical trials, patient concierge services
Industry3 codes
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAE
eConsent & Digital Identity for Trials
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAL
Decentralized/Hybrid Trial Enablement (DCT) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code1 code
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services518
SIC code2 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Prepackaged Software7372
Product category
Clinical Trial Technology Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Technology Platform
TypeSubscription Recurring
Description

Delve Health generates revenue through licensing its unified compliance and retention platform to pharmaceutical, biotech, and medtech sponsors running clinical trials. Revenue derives from platform access, configuration, and per-study deployment. The model involves enterprise contracts with outcomes-scoped integrated engagement rather than pure per-user pricing.

delvehealth.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Enterprise platform licensing with per-study engagement
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. The company sells through direct enterprise sales to pharmaceutical sponsors, biotech companies, medtech firms, and research sites. Engagement is scoped per study with outcomes-accountable pricing.

delvehealth.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Perta
Description

Product of Delve Health

blogs.delvehealth.com
+1 more record
Core offering1 text field

Delve Health provides a unified clinical trial compliance and retention platform combining eCOA/ePRO, wearable and digital endpoint data capture, human multilingual concierge support, eConsent, real-time analytics, and device provisioning. The platform serves pharmaceutical, biotech, medtech, and research site sponsors running decentralized and hybrid clinical trials, with documented 92-98% diary completion and 2-3x retention uplift.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 92-98% diary/ePRO completion range supported by operational follow-up
+8 more records
Product overview1 text field

Delve Health is a clinical trial compliance and retention platform combining eCOA/ePRO, wearables and digital endpoints, human concierge support, eConsent, real-time analytics, and device logistics into a unified operating model. The platform serves pharmaceutical, biotech, medtech, and research site clients across therapeutic areas including dermatology, oncology, rare disease, diabetes/obesity, CNS, cardiology, and respiratory. Key products include the eCOA & ePRO Platform, Wearables & Digital Endpoints (70+ validated algorithms), Concierge-as-a-Service™ (120+ languages), eConsent, Real-Time Analytics Dashboard, Device Provisioning & Logistics, Digital Biomarkers, Site Enablement, Post-Market Studies, Device Integration, and Signal Quality Control — all unified to protect completion, retention, and endpoint integrity in decentralized and hybrid clinical trials.

Product and service1 record
1eCOA & ePRO Platform
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct eCOA/decentralized clinical trial platform competitor with a comparable offering across eCOA, eConsent, telehealth, and wearables. Both target the same pharma/biotech/CRO buyer for hybrid and DCT trial execution.

TypeDirect peer
Description

Direct peer in eCOA, ePRO, and digital endpoints with deep wearable/sensor validation heritage (formerly ERT/Bioclinica). Competes head-to-head in regulated endpoint capture for pharma trials.

TypeDirect peer
Description

Direct eCOA, eConsent, patient engagement, and digital endpoint competitor serving global pharma and biotech. Overlaps Delve in randomization supply, ePRO, and decentralized trial support.

TypeDirect peer
Description

Direct peer in eClinical/eCOA and decentralized trial enablement for pharma and academic sponsors. Comparable mid-market positioning with API-driven eCRF, ePRO, and eConsent.

TypeDirect peer
Description

Direct peer in eCOA, IRT, and clinical supply technology with strong pharma/biotech overlap. Competes on patient-facing data capture and configurable electronic clinical outcome assessments.

TypeDirect peer
Description

Direct decentralized clinical trial platform peer offering eCOA, eConsent, telehealth, and wearables integrations to biopharma. Targets the same DCT operating model as Delve.

TypeDirect peer
Description

Direct virtual/DCT competitor with eCOA, eConsent, and remote monitoring for pharma trials. Comparable patient-facing data capture and decentralized operations focus.

TypeBroad incumbent
Description

Broad incumbent in life sciences cloud (Vault CDB, Vault EDC, Vault CTMS) with growing eCOA and clinical operations footprint. Competes indirectly through bundled enterprise clinical suites.

TypeBroad incumbent
Description

Broad incumbent with Rave EDC, Rave eCOA, and decentralized trial offerings tightly integrated into enterprise pharma workflows. Largest scaled competitor across full clinical operations stack.

TypeEmerging player
Description

Emerging digital endpoint/wearables-focused peer with validated algorithms for respiratory, CNS, and oncology trials. Comparable in digital biomarker and sensor-based endpoint validation but narrower eCOA footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Delve Health

Clinical Trial Technology Platformdelvehealth.com

Delve Health provides a unified clinical trial compliance and retention platform combining eCOA/ePRO, wearable digital endpoints, human concierge support, and real-time analytics. The company serves pharmaceutical, biotech, medtech, and research site clients across 40+ countries and seven therapeutic areas.

What Delve Health does

Delve Health is a private clinical trial technology company founded in 2020 and headquartered in Minneapolis, Delaware-incorporated. The company operates a unified compliance and retention platform combining eCOA/ePRO, wearable-driven digital endpoints, human concierge patient support, multimedia eConsent, real-time analytics, and device logistics into a single operating model. The platform harmonizes signals from 25+ wearable devices through 70+ validated algorithms spanning ECG, glucose/CGM, activity, sleep, respiratory, and cardiovascular modalities, with alignment to FDA Digital Health Technology guidance, the Digital Medicine Society V3 framework, and ICH E6(R3). Concierge-as-a-Service™ provides protocol-trained human patient support in 120+ languages, delivering secondary screening, device troubleshooting, medication reminders, and site escalation workflows with documented outcomes including 92-98% diary completion, 2-3x retention uplift, and 87% deviation prevention. Compliance certifications span HIPAA, GDPR, FDA 21 CFR Part 11, GCP, ISO 9001, and ISO 27001.

Revenue derives from subscription-based enterprise platform licensing sold via direct sales to pharmaceutical sponsors, biotech, medtech, and research site customers across seven therapeutic areas (dermatology, oncology, rare disease, diabetes/obesity, CNS, cardiology, respiratory). Pricing is quote-based and not publicly disclosed; contracts are multi-year and scoped per study. Named customers include Pfizer, Regeneron, and Otsuka (pharma); Inari (biotech); RTI, Atlas, MCRA, and PDC-CRO (CROs); CVS and Rainier Research (sites). The company operates globally across 40+ countries with 3,500+ devices provisioned and supports CTMS integrations with CRIO and Clinical Conductor, plus open API delivery to EDC systems via REST/webhook with CDISC packages. Total disclosed funding is approximately $609K across four rounds from 2015-2024, including a DayOne accelerator participation in August 2024 and prior gBETA Medtech involvement. Leadership includes co-founder and CEO Wessam Sonbol and CTO T Swidan.

Delve Health firmographics

Firmographics
Name
Delve Health
Legal name
Delve Health, Inc.
Website
https://delvehealth.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Delve Health provides a unified clinical trial compliance and retention platform combining eCOA/ePRO, wearable digital endpoints, human concierge support, and real-time analytics. The company serves pharmaceutical, biotech, medtech, and research site clients across 40+ countries and seven therapeutic areas.
Ownership category
akta.pro rank

Delve Health industry classification

Industry
Product category
Clinical Trial Technology Platform
NAICS
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAE
eConsent & Digital Identity for Trials
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAL
Decentralized/Hybrid Trial Enablement (DCT) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Clinical trial technology
  • ECOA ePRO platform
  • Digital biomarkers
  • Decentralized clinical trials
  • Patient concierge services

Where Delve Health is headquartered

Location

Headquarters

HQ city
Golden Valley
HQ country
United States
HQ region
North America

Markets served

Delve Health business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Trial Technology Platform: Delve Health generates revenue through licensing its unified compliance and retention platform to pharmaceutical, biotech, and medtech sponsors running clinical trials. Revenue derives from platform access, configuration, and per-study deployment. The model involves enterprise contracts with outcomes-scoped integrated engagement rather than pure per-user pricing.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise platform licensing with per-study engagement

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Delve Health product offering

Product offering

Core offering

Delve Health provides a unified clinical trial compliance and retention platform combining eCOA/ePRO, wearable and digital endpoint data capture, human multilingual concierge support, eConsent, real-time analytics, and device provisioning. The platform serves pharmaceutical, biotech, medtech, and research site sponsors running decentralized and hybrid clinical trials, with documented 92-98% diary completion and 2-3x retention uplift.

Product overview

Delve Health is a clinical trial compliance and retention platform combining eCOA/ePRO, wearables and digital endpoints, human concierge support, eConsent, real-time analytics, and device logistics into a unified operating model. The platform serves pharmaceutical, biotech, medtech, and research site clients across therapeutic areas including dermatology, oncology, rare disease, diabetes/obesity, CNS, cardiology, and respiratory. Key products include the eCOA & ePRO Platform, Wearables & Digital Endpoints (70+ validated algorithms), Concierge-as-a-Service™ (120+ languages), eConsent, Real-Time Analytics Dashboard, Device Provisioning & Logistics, Digital Biomarkers, Site Enablement, Post-Market Studies, Device Integration, and Signal Quality Control — all unified to protect completion, retention, and endpoint integrity in decentralized and hybrid clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • Perta: Product of Delve Health
  • StudyPal

Products and services

  • eCOA & ePRO Platform

Quantifiable outcome

  • 92-98% diary/ePRO completion range supported by operational follow-up
  • +8 more outcomes

Companies that use Delve Health

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles5 records

Delve Health technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature6 records

Delve Health partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Delve Health competitors and assessment

Company assessment

Direct peers

  • Medable: Direct eCOA/decentralized clinical trial platform competitor with a comparable offering across eCOA, eConsent, telehealth, and wearables. Both target the same pharma/biotech/CRO buyer for hybrid and DCT trial execution.
  • Clario: Direct peer in eCOA, ePRO, and digital endpoints with deep wearable/sensor validation heritage (formerly ERT/Bioclinica). Competes head-to-head in regulated endpoint capture for pharma trials.
  • Signant Health: Direct eCOA, eConsent, patient engagement, and digital endpoint competitor serving global pharma and biotech. Overlaps Delve in randomization supply, ePRO, and decentralized trial support.
  • Castor: Direct peer in eClinical/eCOA and decentralized trial enablement for pharma and academic sponsors. Comparable mid-market positioning with API-driven eCRF, ePRO, and eConsent.
  • YPrime: Direct peer in eCOA, IRT, and clinical supply technology with strong pharma/biotech overlap. Competes on patient-facing data capture and configurable electronic clinical outcome assessments.
  • THREAD Research: Direct decentralized clinical trial platform peer offering eCOA, eConsent, telehealth, and wearables integrations to biopharma. Targets the same DCT operating model as Delve.
  • ObvioHealth: Direct virtual/DCT competitor with eCOA, eConsent, and remote monitoring for pharma trials. Comparable patient-facing data capture and decentralized operations focus.

Broad incumbents

  • Veeva Systems: Broad incumbent in life sciences cloud (Vault CDB, Vault EDC, Vault CTMS) with growing eCOA and clinical operations footprint. Competes indirectly through bundled enterprise clinical suites.
  • Medidata Solutions (Dassault Systèmes): Broad incumbent with Rave EDC, Rave eCOA, and decentralized trial offerings tightly integrated into enterprise pharma workflows. Largest scaled competitor across full clinical operations stack.

Emerging players

  • Koneksa: Emerging digital endpoint/wearables-focused peer with validated algorithms for respiratory, CNS, and oncology trials. Comparable in digital biomarker and sensor-based endpoint validation but narrower eCOA footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Delve Health social profiles

Digital presence

Delve Health compliance and trust

Trust signal

Compliance8 records

Delve Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Delve Health leadership team

Management profile

Number of profiles

Profiles2 records

Delve Health funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Delve Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delve Health

What does Delve Health do?

Delve Health provides a unified clinical trial compliance and retention platform combining eCOA/ePRO, wearable and digital endpoint data capture, human multilingual concierge support, eConsent, real-time analytics, and device provisioning. The platform serves pharmaceutical, biotech, medtech, and research site sponsors running decentralized and hybrid clinical trials, with documented 92-98% diary completion and 2-3x retention uplift.

Is Delve Health a public or private company?

Delve Health is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Delve Health founded?

Delve Health was founded in 2019. It employs 11 to 50 people.

Where is Delve Health based?

Delve Health is headquartered in Golden Valley, United States, in the North America region.

How does Delve Health make money?

One revenue line is on record: clinical Trial Technology Platform.

Who are Delve Health's main competitors?

Direct peers on record are Medable, Clario, Signant Health, Castor, YPrime, THREAD Research and ObvioHealth. Broad incumbents are Veeva Systems and Medidata Solutions (Dassault Systèmes). Koneksa is listed as an emerging player.

Does Delve Health have an API?

Yes. Delve Health offers open endpoint APIs for exporting harmonized endpoints directly to EDC systems, analytics pipelines, and regulatory submission packages. The API supports REST pull and webhook push, batch delivery, CDISC packages, and Parquet format with versioned contracts, provenance, and audit trail. Direct EDC delivery is supported. Note: No public developer portal or SDK documentation URL was found in the source material.

What industry is Delve Health in?

Delve Health's product category is Clinical Trial Technology Platform. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLACAOAE, eConsent & Digital Identity for Trials. Its NAICS code is 518 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comVirtual Clinical Trials Market An Analysis of Size, Shares, Business Growth, and Upcoming Trends Forecast 2026-2033 | Delve Health, Clario, and Clinical InkThe Virtual Clinical Trials market is projected to grow from USD 3,682 million in 2025 to USD 11,487.5 million by 2032, with a CAGR of 17.6%. The market analysis emphasizes key growth drivers, innovation, and strategic initiatives among major players including Delve Health, Clario, and Clinical Ink.Respiratory TherapyHome Care Study to Evaluate BiWaze Clear for BronchiectasisABM Respiratory Care has initiated a multicenter home care study in partnership with Delve Health to evaluate the BiWaze Clear System for treating bronchiectasis patients. The six-month trial will enroll approximately 85 patients across the United States, utilizing remote monitoring and wearable technology to assess the device's ability to reduce pulmonary exacerbations and improve quality of life.GlobeNewswireABM Respiratory Care and Delve Health Launch Home Care Study to Evaluate BiWaze® Clear System in Patients with BronchiectasisABM Respiratory Care and Delve Health have initiated a multi-center home care study to evaluate the BiWaze® Clear System in approximately 85 patients with bronchiectasis across the United States. The six-month post-market trial aims to demonstrate that the system reduces pulmonary exacerbations and improves quality of life through remote monitoring and decentralized clinical trial technology. Patient enrollment began in May 2025, with the study expected to conclude in 18 months.openPR.comVirtual Clinical Trials Market to Witness Remarkable Growth with Delve Health, Clario, Clinical Ink, Castor, Thread, Science 37The virtual clinical trials market is projected to grow from USD 3,682 million in 2025 to USD 11,487.5 million by 2032, a CAGR of 17.65%. The report also covers key players, segmentation, and regional outlook.CCX MediaGolden Valley Med-Tech Startup Companies Receive State FundingThe Minnesota Department of Employment and Economic Development awarded $400,000 in Launch Minnesota Business Operation Innovation Grants to several startup companies, including Delve Health. Delve Health will utilize its approximately $30,000 grant to expand its digital platform for clinical trial data collection and support its marketing efforts during a growth period. Other recipients of the grants include AcQumen Medical and Daynamica.DelvehealthDelve Health's Advanced Integration ServicesDelve Health is promoting its Clinical StudyPal platform, which integrates digital biomarkers collected from wearables and sensors into clinical trials to enhance patient monitoring and data analysis. The service utilizes advanced analytics and machine learning to provide real-time insights, improve data accuracy, and ensure regulatory compliance for research sites.YahooDelve Health and AliveCor Collaborate to Revolutionize Digital Healthcare Solutions in CardiologyDelve Health announced a collaboration with AliveCor to integrate the KardiaMobile 6L EKG device into its LiveCare Link+ smart RPM gateway. The partnership aims to improve cardiac monitoring, accelerate drug development, and collect real-world data for clinical trials. The KardiaMobile 6L is the first FDA-cleared six-lead personal EKG.PR NewswireDelve Health and cerascreen® Announce a Partnership to Offer a "One-Stop Solution" Digital Healthcare AppDelve Health, a virtual health and technology firm based in Minneapolis, and cerascreen®, an at-home health diagnostic testing company headquartered in Germany, announced a partnership to offer a combined digital healthcare solution using smart and wearable devices. The partnership integrates cerascreen's at-home testing kits with Delve Health's customizable mobile and web-based platform, enabling consumers to monitor and track their health data across multiple devices and operating systems. The companies stated this collaboration aims to expand global access to affordable digital healthcare by removing social determinants of health barriers.PR NewswireDelve Health and UW Medicine Announce a Collaboration to Access Remote Data Capture for Diabetes ResearchDelve Health and UW Medicine announced a collaboration to conduct NIH-funded diabetes research using artificial intelligence and remote patient monitoring through wearable devices. The study, called AI-READI, will collect data from more than 4,000 participants across the United States, balancing for race/ethnicity and diabetes severity to build unbiased machine learning models for Type 2 Diabetes insights. UW Medicine researchers aim to use the data to identify factors that promote wellbeing and accelerate machine learning applications in diabetes research.